Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact The Gross Law Firm

Core Viewpoint - The Gross Law Firm is notifying shareholders of Cassava Sciences, Inc. regarding a class action lawsuit related to the company's drug candidate simufilam, which failed to meet key study endpoints, leading to a significant drop in stock price [1][2]. Group 1: Allegations and Impact - The allegations state that Cassava Sciences provided misleading information about simufilam's effectiveness in treating Alzheimer's Disease, expressing confidence in its performance [1]. - Following the release of disappointing Phase 3 study results on November 25, 2024, Cassava's stock plummeted from $26.48 to $4.30, marking a decline of approximately 83.76% in one day [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 7, 2024, to November 24, 2024, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is February 10, 2025, and there are no costs associated with participating in the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].